| Literature DB >> 31652858 |
Zhong Peng1,2, Xiaosong Li3,4, Zizhe Hu5,6, Zugang Li7,8, Yujin Lv9,10, Minggang Lei11, Bin Wu12,13, Huanchun Chen14,15, Xiangru Wang16,17.
Abstract
The emergence of carbapenem-resistant and colistin-resistant Enterobacteriaceae represents a great risk for public health. In this study, the phenotypical and genetic characteristics of eight carbapenem-resistant and colistin-resistant isolates from pig farms in China were determined by the broth microdilution method and whole genome sequencing. Antimicrobial susceptibility testing showed that the eight carbapenem-resistant and colistin-resistant strains were resistant to three aminoglycosides, twelve β-lactams, one of the phenicols, one of the tetracyclines, and one of the fluoroquinolones tested, simultaneously. The prediction of acquired resistant genes using the whole genome sequences revealed the co-existence of blaNDM-1 and mcr-1 as well as the other genes that were responsible for the multidrug-resistant phenotypes. Bioinformatics analysis also showed that the carbapenem-resistant gene blaNDM-1 was located on a putative IncFII-type plasmid, which also carried the other acquired resistant genes identified, including fosA3, blaTEM-1B and rmtB, while the colistin-resistant gene mcr-1 was carried by a putative IncX4-type plasmid. Finally, we found that these resistant genes/plasmids were conjugative, and they could be co-conjugated, conferring resistance to multiple types of antibiotics, including the carbapenems and colistin, to the recipient Escherichia coli strains.Entities:
Keywords: Escherichia coli; blaNDM-1; carbapenem-resistance; co-existence; colistin-resistance; mcr-1; plasmid
Year: 2019 PMID: 31652858 PMCID: PMC6920953 DOI: 10.3390/microorganisms7110482
Source DB: PubMed Journal: Microorganisms ISSN: 2076-2607
Figure 1Antimicrobial susceptibility profile of the eight carbapenem-resistant and colistin-resistant Escherichia coli isolates. (A) Heatmap showing resistance and multidrug resistance phenotypes of each of the E. coli isolates; (B) Percent strains resistant to the tested antibiotics. AMK: amikacin; GEN: gentamicin; TOB: tobramycin; ETP: ertapenem; IPM: imipenem; MRP: meropenem; CFZ: cefazolin; CFX: cefuroxime; FOX: cefoxitin; CAZ: ceftazidime; CRO: ceftriaxone; CPM: cefepime; AMC: amoxicillin/clavulanate; AMS: ampicillin/sulbactam; PTZ: piperacillin/tazobactam; CL: colistin; CHL: chloramphenicol; MXF: moxifloxacin; CIP: ciprofloxacin; LVX: levofloxacin; NOR: norfloxacin; TET: tetracycline; MIN: minocycline; SXT: trimethoprim/sulfamethoxazole; AZM: aztreonam; FOS: Fosfomycin; NIT: nitrofurantoin; TGC: tigecycline.
Figure 2PCR detection of the carbapenem-resistant gene bla and the colistin-resistant gene mcr-1 from (A) the plasmids extracted from the eight carbapenem-resistant and (B) the colistin-resistant E. coli strains. M: DL 2000 DNA marker; 1–8: plasmid from RXD007, RXD012, RXD020, RXD024, RXD033, RXD035, RXD100, and RXD115; 9: ddH2O as negative control.
Figure 3Heatmap showing acquired resistant genes identified in each of the eight carbapenem-resistant and colistin-resistant E. coli isolates.
Figure 4Phylogenetic analysis of the eight carbapenem-resistant and colistin-resistant E. coli isolates. Sequence types, O-serotypes, H-serotypes, and plasmid replicons are also shown. The evolutionary history was inferred by using the Maximum Likelihood method and Tamura–Nei model. The tree with the highest log likelihood (−13321.25) is shown. The percentage of trees in which the associated taxa clustered together is shown next to the branches. Initial tree(s) for the heuristic search were obtained automatically by applying Neighbor-Join and BioNJ algorithms to a matrix of pairwise distances estimated using the Maximum Composite Likelihood (MCL) approach, and then selecting the topology with superior log likelihood value. The tree is drawn to scale, with branch lengths measured in the number of substitutions per site. This analysis involved nine nucleotide sequences. There was a total of 9093 positions in the final dataset. Evolutionary analyses were conducted by using MEGA X. The circles denote bootstrap values within the range of 0.19–1.000.
Figure 5Comparison of plasmid pHNEC55 (panel A) and pIBMC_mcr1 (panel B) with the genomes of RXD007, RXD012, RXD020, RXD024, RXD033, RXD035, RXD100, and RXD115, displayed as the outer rings inside to outside, respectively. The outmost rings (red) show the functional genes including the resistance genes as well as the structural genes carried by pHNEC55 (panel A) and pIBMC_mcr1 (panel B).
Phenotypic characteristics of the transconjugants of the eight carbapenem-resistant and colistin-resistant E. coli.
| Antibiotics tested | Transconjugants selected by rifampin plus imipenem plus colistin | E. coli C600 | ||||||
|---|---|---|---|---|---|---|---|---|
| Minimum inhibitory concentration (μg/ml) | ||||||||
| Cir007 1 | Cir012 | Cir020 | Cir033 | Cir035 | Cir100 | Cir115 | ||
| Amikacin | > 32 (R1) | > 32 (R) | > 32 (R) | > 32 (R) | > 32 (R) | > 32 (R) | > 32 (R) | ≤ 8 (S) |
| Gentamicin | > 8 (R) | > 8 (R) | > 8 (R) | > 8 (R) | > 8 (R) | > 8 (R) | > 8 (R) | ≤ 2 (S) |
| Tobramycin | > 8 (R) | > 8 (R) | > 8 (R) | > 8 (R) | > 8 (R) | > 8 (R) | > 8 (R) | ≤ 2 (S) |
| Ertapenem | > 2 (R) | > 2 (R) | > 2 (R) | > 2 (R) | > 2 (R) | > 2 (R) | 2 (R) | ≤ 0.25 (S) |
| Imipenem | > 8 (R) | > 8 (R) | > 8 (R) | > 8 (R) | > 8 (R) | 1 (S) | 8 (R) | 0.5 (S) |
| Meropenem | > 8 (R) | > 8 (R) | > 8 (R) | > 8 (R) | > 8 (R) | 1 (S) | 4 (R) | ≤ 0.13 (S) |
| Cefazolin | > 16 (R) | > 16 (R) | > 16 (R) | > 16 (R) | > 16 (R) | > 16 (R) | > 16 (R) | 4 (S) |
| Cefuroxime | > 16 (R) | > 16 (R) | > 16 (R) | > 16 (R) | > 16 (R) | > 16 (R) | > 16 (R) | 16 (R) |
| Cefoxitin | > 16 (R) | > 16 (R) | > 16 (R) | > 16 (R) | > 16 (R) | > 16 (R) | > 16 (R) | 8 (S) |
| Ceftazidime | > 32 (R) | > 32 (R) | > 32 (R) | > 32 (R) | > 32 (R) | > 32 (R) | > 32 (R) | ≤ 1 (S) |
| Ceftriaxone | > 32 (R) | > 32 (R) | > 32 (R) | > 32 (R) | > 32 (R) | > 32 (R) | > 32 (R) | ≤ 1 (S) |
| Cefepime | > 16 (R) | > 16 (R) | > 16 (R) | 16 (R) | > 16 (R) | 16 (R) | 8 (R) | ≤ 1 (S) |
| Amoxicillin/clavulanate | > 32/16 (R) | > 32/16 (R) | > 32/16 (R) | > 32/16 (R) | > 32/16 (R) | 32/16 (R) | 32/16 (R) | ≤ 8/4 (S) |
| Ampicillin/sulbactam | >16/8 (R) | >16/8 (R) | >16/8 (R) | >16/8 (R) | > 16/8 (R) | > 16/8 (R) | >16/8 (R) | 8/4 (S) |
| Piperacillin/tazobactam | >64/4 (R) | >64/4 (R) | >64/4 (R) | >64/4 (R) | >64/4 (R) | >64/4 (R) | >64/4 (R) | ≤ 4/4 (S) |
| Colistin | > 4 (R) | > 4 (R) | 4 (R) | 4 (R) | 4 (R) | > 4 (R) | > 4 (R) | ≤ 1 (S) |
| Chloramphenicol | > 16 (R) | > 16 (R) | > 16 (R) | ≤ 4 (S) | ≤ 4 (S) | > 16 (R) | ≤ 4 (S) | ≤ 4 (S) |
| Moxifloxacin | > 2 (R) | > 2 (R) | > 2 (R) | ≤ 0.5 (S) | ≤ 0.5 (S) | > 2 (R) | ≤ 0.5 (S) | ≤ 0.5 (S) |
| Ciprofloxacin | > 4 (R) | > 4 (R) | > 4 (R) | ≤ 0.5 (S) | ≤ 0.5 (S) | 2 (I) | ≤ 0.5 (S) | ≤ 0.5 (S) |
| Levofloxacin | > 8 (R) | > 8 (R) | > 8 (R) | ≤ 1 (S) | ≤ 1 (S) | 2 (S) | ≤ 1 (S) | ≤ 1 (S) |
| Norfloxacin | > 8 (R) | > 8 (R) | > 8 (R) | ≤ 2 (S) | ≤ 2 (S) | 4 (S) | ≤ 2 (S) | ≤ 2 (S) |
| Tetracycline | > 8 (R) | > 8 (R) | > 8 (R) | ≤ 2 (S) | ≤ 2 (S) | > 8 (R) | ≤ 2 (S) | ≤ 2 (S) |
| Minocycline | 4 (S) | 4 (S) | 4 (S) | ≤ 1 (S) | 2 (S) | 16 (R) | 2 (S) | ≤ 1 (S) |
| Trimethoprim/sulfamethoxazole | > 4/76 (R) | > 4/76 (R) | > 4/76 (R) | ≤1/19 (S) | ≤ 1/19 (S) | ≤ 1/19 (S) | ≤1/19 (S) | ≤ 1/19 (S) |
| Aztreonam | ≤ 2 (S) | ≤ 2 (S) | ≤ 2 (S) | ≤ 2 (S) | ≤ 2 (S) | ≤ 2 (S) | ≤ 2 (S) | ≤ 2 (S) |
| Fosfomycin | > 128 (R) | > 128 (R) | > 128 (R) | ≤ 16 (S) | ≤ 16 (S) | ≤ 16 (S) | > 128 (R) | ≤ 16 (S) |
| Nitrofurantoin | ≤ 16 (S) | 32 (S) | ≤ 16 (S) | ≤ 16 (S) | ≤ 16 (S) | > 64 (R) | ≤ 16 (S) | ≤ 16 (S) |
| Tigecycline | ≤ 1 (S) | ≤ 1 (S) | ≤ 1 (S) | ≤ 1 (S) | ≤ 1 (S) | ≤ 1 (S) | ≤ 1 (S) | ≤ 1 (S) |
1 Note: Cir007, Cir012, Cir020, Cir033, Cir035, Cir100, and Cir115 represent the transconjugant of RXD007, RXD012, RXD020, RXD033, RXD035, RXD100, and RXD115, respectively. R: Resistant; S: susceptible; I: intermediately resistant.